The Role of Serum Biomarkers in Predicting Fibrosis Progression in Pediatric and Adult Hepatitis C Virus Chronic Infection
作者： Pamela Valva , Paola Casciato , Juan M Diaz Carrasco , Adrian Gadano , Omar Galdame
DOI: 10.1371/JOURNAL.PONE.0023218
关键词:
摘要: Background/Aims Liver biopsy represents the gold standard for damage evaluation, but noninvasive serum markers that mirror liver fibrosis progression are actual goals both in adults and especially children. The aim was to determine specific correlate with during chronic HCV infection.
paperity.org
core.ac.uk 参考文章(61)
Pornpen Thampanitchawong, Teerha Piratvisuth, Liver biopsy:complications and risk factors. World Journal of Gastroenterology. ,vol. 5, pp. 301- 304 ,(2000) , 10.3748/WJG.V5.I4.301
D. R. Nelson, R. P. Gonzalez‐Peralta, K. Qian, Y. Xu, C. G. Marousis, G. L. Davis, J. Y. N. Lau, Transforming growth factor-beta 1 in chronic hepatitis C. Journal of Viral Hepatitis. ,vol. 4, pp. 29- 35 ,(1997) , 10.1046/J.1365-2893.1997.00124.X
Giada Sebastiani, Alfredo Alberti, Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy World Journal of Gastroenterology. ,vol. 12, pp. 3682- 3694 ,(2006) , 10.3748/WJG.V12.I23.3682
S. M. Martinez, G. Fernández-Varo, P. González, E. Sampson, M. Bruguera, M. Navasa, W. Jiménez, J. M. Sánchez-Tapias, X. Forns, Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C Alimentary Pharmacology & Therapeutics. ,vol. 33, pp. 138- 148 ,(2011) , 10.1111/J.1365-2036.2010.04500.X
Abeer M. Elmahalaway, Sami H. Abuhashem, Adel M. Ahmed, Ibrahim M. Elmetwally, Determination of serum fibrosis index in patients with chronic hepatitis and its relationship to histological activity index. Saudi Medical Journal. ,vol. 30, pp. 638- 646 ,(2009)
Norma I. Rallón, Pablo Barreiro, Vincent Soriano, Javier García-Samaniego, Mariola López, José M. Benito, Elevated TGF-β1 levels might protect HCV/ HIV-coinfected patients from liver fibrosis. European Journal of Clinical Investigation. ,vol. 41, pp. 70- 76 ,(2011) , 10.1111/J.1365-2362.2010.02381.X
J. Parkes, I. N. Guha, P. Roderick, S. Harris, R. Cross, M. M. Manos, W. Irving, A Zaitoun, M. Wheatley, S. Ryder, W. Rosenberg, Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C Journal of Viral Hepatitis. ,vol. 18, pp. 23- 31 ,(2011) , 10.1111/J.1365-2893.2009.01263.X
J Macías, JA Mira, I Gilabert, K Neukam, C Roldán, MaMar Viloria, A Moro, JA Pineda, Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. Hiv Medicine. ,vol. 12, pp. 14- 21 ,(2011) , 10.1111/J.1468-1293.2010.00836.X
A. M. Gressner, R. Weiskirchen, Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF‐β as major players and therapeutic targets Journal of Cellular and Molecular Medicine. ,vol. 10, pp. 76- 99 ,(2006) , 10.1111/J.1582-4934.2006.TB00292.X
Robert J Fontana, Herbert L Bonkovsky, Deepa Naishadham, Jules L Dienstag, Richard K Sterling, Anna SF Lok, Grace L Su, Halt–C Trial Group, Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients with Advanced Fibrosis Clinical Gastroenterology and Hepatology. ,vol. 7, pp. 219- 226 ,(2009) , 10.1016/J.CGH.2008.10.034